Evidence map›Paper›PMID 33172929›Full record

ArticleCancer research2021

Loss of Aurora Kinase Signaling Allows Lung Cancer Cells to Adopt Endoreplication and Form Polyploid Giant Cancer Cells That Resist Antimitotic Drugs.

Vural Tagal, Michael G Roth

Open access · bronzeAbstract read
In one paragraph

Article in Cancer research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
3.4field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 58 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Cells in the Polyaneuploid Cancer Cell State are Pro-Metastatic.bioRxiv : the preprint server for biology · 2024
    Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Targeting BCL2 Overcomes Resistance and Augments Response to Aurora Kinase B Inhibition by AZD2811 in Small Cell Lung Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Vural TagalDepartment of Biochemistry, University of Texas Southwestern Medical Center, Dallas, Texas. vural.tagal@utsouthwestern.edu.
Michael G RothDepartment of Biochemistry, University of Texas Southwestern Medical Center, Dallas, Texas.
The University of Texas Southwestern Medical Center · US

Funding

UNIVERSITY OF TEXAS--SPORE IN LUNG CANCERP50CA070907 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI HEYMACH, JOHN V., MINNA, JOHN D. · 1996 to 2024
$57.4M
Lung cancer oncogenotype-selective drug target discoveryU01CA176284 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI MACMILLAN, JOHN B, MINNA, JOHN D. · 2013 to 2016
$2.8M
HTS for discovery of inhibitors of the centrosome-independent mitotic spindle machineryR01CA221978 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI ROTH, MICHAEL G · 2018 to 2020
$1.1M
NCI NIH HHS P50 CA070907NCI NIH HHS R01 CA221978NCI NIH HHS U01 CA176284
6 · The paper itself

Abstract

Polyploid giant cancer cells (PGCC) are common in tumors and have been associated with resistance to cancer therapy, tumor relapse, malignancy, immunosuppression, metastasis, cancer stem cell production, and modulation of the tumor microenvironment. However, the molecular mechanisms that cause these cells to form are not yet known. In this study, we discover that Aurora kinases are synergistic determinants of a switch from the proliferative cell cycle to polyploid growth and multinucleation in lung cancer cell lines. When Aurora kinases were inhibited together, lung cancer cells uniformly grew into multinucleated PGCCs. These cells adopted an endoreplication in which the genome replicates, mitosis is omitted, and cells grow in size. Consequently, such cells continued to safely grow in the presence of antimitotic agents. These PGCC re-entered the proliferative cell cycle and grew in cell number when treatment was terminated. Thus, PGCC formation might represent a fundamental cellular response to Aurora kinase inhibitors and contributes to therapy resistance or tumor relapse. SIGNIFICANCE: These findings provide a novel insight about how cancer cells respond to Aurora kinase inhibitors and identify a new mechanism responsible for resistance to these agents and other antimitotic drugs.

Indexed as

Drug Resistance, NeoplasmAntimitotic AgentsApoptosisAurora Kinase AAurora Kinase BBiomarkers, TumorCell ProliferationEndoreduplicationGene Expression Regulation, NeoplasticGiant CellsHumansLung NeoplasmsNeoplastic Stem CellsTumor Cells, CulturedTumor MicroenvironmentAntimitotic AgentsAURKA protein, humanAURKB protein, humanAurora Kinase AAurora Kinase BBiomarkers, Tumor

Identifiers

PMID33172929
PMCPMC8788927
OpenAlexW3104439436

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.